TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal,Neal D. Shore,Curtis Dunshee,Lawrence Ivan Karsh,Arun Azad,André P. Fay,Joan Carles,Beth Sullivan,Nicola Di Santo,Mohamed Elmeliegy,Xun Lin,Ruben G. W. Quek,Akos Czibere,Karim Fizazi

TALAPRO-2: A placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC).

2020

Neeraj Agarwal
Neal D. Shore
Curtis Dunshee
Lawrence Ivan Karsh
Arun Azad
André P. Fay
Joan Carles
Beth Sullivan
Nicola Di Santo
Mohamed Elmeliegy
Xun Lin
Ruben G. W. Quek
Akos Czibere
Karim Fizazi

TPS264Background: TALA is a poly(ADP-ribose) polymerase (PARP) inhibitor that inhibits PARP1/2 and traps PARP on DNA, preventing DNA damage repair (DDR) and causing death of cells with DDR mutation...

Keywords:

Castration
Pathology
PARP1
Talazoparib
Prostate cancer
Cancer research
Mutation
Polymerase
Enzalutamide
Poly ADP ribose polymerase
Medicine
Placebo

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations